Prescription medicine
Filgrastim Brand names: Nypozi, Neupogen, Releuko, Granix, Nivestym
Filgrastim (Neupogen) is a prescription medicine with an FDA approval on record since 1991. No generic is listed; pharmacies paid $650.05 per mL (Neupogen 300 mcg/0.5 mL syringe) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the filgrastim FDA label on DailyMed (effective July 23, 2026, Amgen, Inc); the BLA 103353 record on Drugs@FDA; every filgrastim label on DailyMed.
Highlights of the record
FDA label of July 23, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment o
Forms and strengths
- 0.5ml
- 0.8ml
- 1.6ml
Injection (solution); injection.
On the market
- Earliest approval on file
- February 20, 1991 Neupogen, Amgen; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 8 of which 0 under generic applications, 8 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $650.05 per mL Neupogen 300 mcg/0.5 mL syringe
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 3 since 2025 0 Class I among all firms' recalls; latest February 27, 2025
- FAERS reports
- 41,194 through July 30, 2026
What is filgrastim used for?
From the label: indications and usageNEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation […]
FDA pharmacologic class: Leukocyte Growth Factor.
Source: FDA drug label (NEUPOGEN), Amgen, Inc, effective July 23, 2026 (SPL set 97cc73cc-b5b7-458a-a933-77b00523e193), via openFDA; the full label on DailyMed
Is there a generic for filgrastim (Neupogen)?
No generic filgrastim is approved (Drugs@FDA, October 8, 2026).
- 1991 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for filgrastim (Neupogen)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $650.05 per mL (Neupogen 300 mcg/0.5 mL syringe), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Neupogen 300 mcg/mL vial (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Neupogen 300 mcg/0.5 mL syringe | Brand | $650.05 per mL | n/a | -0.1% |
| Neupogen 300 mcg/mL vial | Brand | $304.09 per mL | n/a | -0.6% |
| Zarxio 300 mcg/0.5 mL syringe | Brand | $531.65 per mL | $265.83 per single-dose syringe | no change |
| Zarxio 480 mcg/0.8 mL syringe | Brand | $533.41 per mL | $426.73 per single-dose syringe | +0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has filgrastim been recalled?
The FDA's Enforcement Report lists 3 recalls naming filgrastim since 2025: 0 Class I (the most serious), 3 Class II, 0 Class III; 3 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| February 27, 2025 | Class II | Amgen, Inc. | Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months. |
| January 10, 2025 | Class II | Teva Pharmaceuticals USA, Inc | Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the filgrastim label say about other medicines?
The filgrastim label names 1 other medicine in its interaction, contraindication or warning sections. The labels of 6 other medicines name filgrastim. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Pegfilgrastim | contraindications | CONTRAINDICATIONS NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim [see Warnings and Precautions (5.3) ]. |
Other labels that name filgrastim
Source: FDA drug label (NEUPOGEN), Amgen, Inc, effective July 23, 2026 (SPL set 97cc73cc-b5b7-458a-a933-77b00523e193), via openFDA; the full label on DailyMed
What do FAERS reports show for filgrastim?
The FDA Adverse Event Reporting System holds 41,194 reports that list filgrastim among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 9,304 are coded as a death and 17,754 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other leukocyte growth factors
- the pharmacologic class, with prices and generics
- Filgrastim side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other